fig5

An activated CD8<sup>+</sup> T cell-based signature stratifies prognosis and suggests differential sensitivity to immune checkpoint inhibitors in hepatocellular carcinoma

Figure 5. Construction and verification of the risk model. (A) PCA of the 17 hub genes; (B) Kaplan-Meier survival curves for high-risk vs. low-risk groups in the TCGA cohort; (C) ROC curve reached 0.55; (D) Sankey diagram illustrating relationships among molecular clusters, risk groups, and key clinical features; (E and F) External validation of the risk model in GEO datasets GSE76427 and GSE14520. PCA: Principal component analysis; TCGA: the Cancer Genome Atlas; ROC: receiver operating characteristic; GEO: the Gene Expression Omnibus; OS: overall survival; AUC: area under the ROC curve.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/